We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




SNP Database Now Available to Genomics Researchers

By LabMedica International staff writers
Posted on 18 Aug 2010
Advanced genomics researchers now have access to collections comprising up to 7.4 million single-nucleotide polymorphisms (SNPs) that can be used to assemble microarrays containing from 50,000 to 2.6 million SNPs.

Access to this unprecedented collection of genomic material is through the Affymetrix Inc. More...
(Santa Clara, CA, USA) Axiom Genomic Database. This collection of validated common and rare SNPs includes 7.4 million SNPs from the 1000 Genomes Project, the International HapMap Project, and other sources.

Investigators can also combine SNPs from their own sequencing projects and other sources with Affymetrix' validated SNPs to design arrays with up to 2.6 million SNPs. In the near future, this capability will expand to support custom array designs containing more than 5 million SNPs. Investigators working with the Affymetrix Genome Database will receive design support and expertise from the Affymetrix team of bioinformatics scientists to ensure streamlined SNP selection and intelligently designed arrays that fulfill the objectives of their study.

"As the needs of human disease research evolve with the rapid expansion of available markers, customization, and flexibility have become increasingly important,” said Kevin King, president and CEO of Affymetrix. "Researchers want to design studies to optimize their ability to answer key biological questions. Axiom Custom Genotyping Arrays enable them to do this with a wide range of formats, relevant content, and high-quality data to expedite their disease association studies.”

Related Links:

Affymetrix Inc.



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Drug Testing Assays
Atellica DT 250 Analyzer
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.